Alamar Biosciences has launched the NULISAseq Immune 340 Panel, its broadest multiplexed immune profiling solution for translational research and drug development.
The panel measures approximately 340 immune-related proteins simultaneously from a single sample. It expands on the NULISAseq Inflammation Panel 250 and supports immune proteome profiling across cancer, cardiovascular and metabolic diseases, autoimmune diseases, and aging research.
Many immune mediators circulate at concentrations ranging from fg/mL to sub-pg/mL, below the detection limits of conventional immunoassays. These targets include cytokines, chemokines, cell death pathway markers, checkpoint inhibitors, metabolic regulators, and co-stimulatory signals.
The panel combines broad coverage with high sensitivity to detect proteins that other methods have failed to measure. Researchers can examine these low-abundance proteins alongside established markers in one multiplexed run.
“The immune system holds some of the earliest and most informative signals of disease, yet much of that biology has been out of reach,” comments Dr. Yuling Luo, founder, chief executive officer and chair of Alamar. “NULISAseq Immune 340 gives researchers an unprecedented view of immune activity.”
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
Immune responses involve pathway crosstalk, feedback loops, and cooperation between cell types. Researchers need multi-protein context to interpret this activity and identify cytokines and other biomarkers that signal disease before symptoms appear.
The panel also targets proteins linked to inflammaging. This chronic, low-grade inflammation builds with age as immune senescence and neuroimmune activation contribute to cardiovascular, metabolic, neurodegenerative, and cancer risk.
“What makes the NULISAseq Immune 340 Panel distinctive is the combination of breadth and sensitivity,” remarks Bailin Zhang, PhD, head of exploratory biomarkers in the Translational Medicine Unit at Sanofi. “Having access to them, alongside the canonical markers, in one multiplexed run opens new possibilities for biomarker discovery and patient stratification.”
Alamar’s precision proteomics platform combines its proprietary NULISA technology with the ARGO HT System. The platform offers high sensitivity, high specificity, flexible multiplexing, broad dynamic range, and automation for detecting protein biomarkers at extremely low concentrations in blood.
This article is based on a press release issued by Alamar Biosciences.
